Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
North Texas Endocrine Center
mi
from
Dallas, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
North Texas Endocrine Center
mi
from
Dallas, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
SAM Clinical Research Center
mi
from
San Antonio, TX
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
SAM Clinical Research Center
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1264.3.01020 Boehringer Ingelheim Investigational Site
mi
from
Muscle Shoals, AL
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1264.3.01020 Boehringer Ingelheim Investigational Site
mi
from
Muscle Shoals, AL
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
9.197.001 Boehringer Ingelheim Investigational Site
mi
from
Tempe, AZ
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
9.197.001 Boehringer Ingelheim Investigational Site
mi
from
Tempe, AZ
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.19.10070 Boehringer Ingelheim Investigational Site
mi
from
Irvine, CA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.19.10070 Boehringer Ingelheim Investigational Site
mi
from
Irvine, CA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.19.10047 Boehringer Ingelheim Investigational Site
mi
from
La Mesa, CA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.19.10047 Boehringer Ingelheim Investigational Site
mi
from
La Mesa, CA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
205.452.01089 Boehringer Ingelheim Investigational Site
mi
from
Rancho Cucamonga, CA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
205.452.01089 Boehringer Ingelheim Investigational Site
mi
from
Rancho Cucamonga, CA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.19.10141 Boehringer Ingelheim Investigational Site
mi
from
Milford, CT
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.19.10141 Boehringer Ingelheim Investigational Site
mi
from
Milford, CT
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
205.452.01184 Boehringer Ingelheim Investigational Site
mi
from
Jupiter, FL
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
205.452.01184 Boehringer Ingelheim Investigational Site
mi
from
Jupiter, FL
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.25.10062 Boehringer Ingelheim Investigational Site
mi
from
Plantation, FL
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
205.452.01021 Boehringer Ingelheim Investigational Site
mi
from
Dubuque, IA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
205.452.01021 Boehringer Ingelheim Investigational Site
mi
from
Dubuque, IA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.25.10071 Boehringer Ingelheim Investigational Site
mi
from
Dearborn, MI
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.25.10071 Boehringer Ingelheim Investigational Site
mi
from
Dearborn, MI
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1199.14.1083 Boehringer Ingelheim Investigational Site
mi
from
Henderson, NV
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1199.14.1083 Boehringer Ingelheim Investigational Site
mi
from
Henderson, NV
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1218.61.01029 Boehringer Ingelheim Investigational Site
mi
from
Brooklyn, NY
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1218.61.01029 Boehringer Ingelheim Investigational Site
mi
from
Brooklyn, NY
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.19.10059 Boehringer Ingelheim Investigational Site
mi
from
New Hyde Park, NY
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.19.10059 Boehringer Ingelheim Investigational Site
mi
from
New Hyde Park, NY
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.23.10123 Boehringer Ingelheim Investigational Site
mi
from
Smithtown, NY
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.23.10123 Boehringer Ingelheim Investigational Site
mi
from
Smithtown, NY
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
205.452.01348 Boehringer Ingelheim Investigational Site
mi
from
Salisbury, NC
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
205.452.01348 Boehringer Ingelheim Investigational Site
mi
from
Salisbury, NC
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.20.10130 Boehringer Ingelheim Investigational Site
mi
from
Gallipolis, OH
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.20.10130 Boehringer Ingelheim Investigational Site
mi
from
Gallipolis, OH
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.25.10091 Boehringer Ingelheim Investigational Site
mi
from
Marion, OH
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.25.10091 Boehringer Ingelheim Investigational Site
mi
from
Marion, OH
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1245.25.10004 Boehringer Ingelheim Investigational Site
mi
from
Norfolk, VA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1245.25.10004 Boehringer Ingelheim Investigational Site
mi
from
Norfolk, VA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
1199.15.10112 Boehringer Ingelheim Investigational Site
mi
from
Vancouver, WA
Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
Status: Archived
Updated: 1/1/1970
1199.15.10112 Boehringer Ingelheim Investigational Site
mi
from
Vancouver, WA
The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients
The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients
The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
Status: Archived
Mills-Peninsula Health Services
mi
from
San Mateo, CA
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
Status: Archived
Updated: 1/1/1970
Mills-Peninsula Health Services
mi
from
San Mateo, CA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Baystate Med Ctr of Springfield
mi
from
Springfield, MA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Baystate Med Ctr of Springfield
mi
from
Springfield, MA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Center for Fertility and Women's Health
mi
from
New Britain, CT
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Center for Fertility and Women's Health
mi
from
New Britain, CT
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Aurora, CO
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Aurora, CO
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Abington Memorial Hospital
mi
from
Abington, PA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Abington Memorial Hospital
mi
from
Abington, PA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Oak Lawn, IL
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Oak Lawn, IL
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Inova Fairfax
mi
from
Falls Church, VA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Inova Fairfax
mi
from
Falls Church, VA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Lexington, KY
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lexington, KY
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Camden, NJ
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Camden, NJ
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
New York, NY
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New York, NY
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Pawtucket, RI
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Pawtucket, RI
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Salt Lake City, UT
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Salt Lake City, UT
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Clinical Research Facility
mi
from
Seattle, WA
A Dose-Range Finding Study in Patient With Type 2 Diabetes (MK-3102-006 EXT1)
A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Seattle, WA
Evaluation of Pharmacokinetics, Safety, And Tolerability Of PF-04971729 In Japanese And Western Healthy Subjects
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Parallel Cohort, Single Dose Escalation And Multiple Dose Study In Japanese Healthy Subjects, And Open Label, Single Dose Escalation Study In Western Healthy Subjects To Investigate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729
Status: Archived
Pfizer Investigational Site
mi
from
Bridgeport, CT
Evaluation of Pharmacokinetics, Safety, And Tolerability Of PF-04971729 In Japanese And Western Healthy Subjects
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Parallel Cohort, Single Dose Escalation And Multiple Dose Study In Japanese Healthy Subjects, And Open Label, Single Dose Escalation Study In Western Healthy Subjects To Investigate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bridgeport, CT
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
An Open Label Randomized Crossover Study to Assess Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial/Syringe Method of Insulin Glargine (Lantus) Injection Therapy in Patients With T2DM
Status: Archived
Sanofi-Aventis Administrative Office
mi
from
Bridgewater, NJ
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
An Open Label Randomized Crossover Study to Assess Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial/Syringe Method of Insulin Glargine (Lantus) Injection Therapy in Patients With T2DM
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Administrative Office
mi
from
Bridgewater, NJ
We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans
A Mindfulness-based Intervention to Reduce Diabetes Risk in Pre-diabetic African Americans
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans
A Mindfulness-based Intervention to Reduce Diabetes Risk in Pre-diabetic African Americans
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL